A systematic review of matrix metalloproteinase 9 as a biomarker of survival in patients with osteosarcoma

Tumor Biology

Volumn 35, Issue 6, 2014, Pages 5487-5491

  Li, Hui ^a   Zhang, Kun ^a   Liu, Li Hong ^a   Ouyang, Yurong ^a   Bu, Jie ^a   Guo, Hong Bin ^a   Xiao, Tao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Matrix metalloproteinase 9; Meta analysis; Osteosarcoma; Prognosis

Indexed keywords

GELATINASE B;

ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MIGRATION; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; META ANALYSIS; METASTASIS; OSTEOSARCOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; SURVIVAL RATE; SYSTEMATIC REVIEW; TUMOR INVASION;

BONE NEOPLASMS; HUMANS; MATRIX METALLOPROTEINASE 9; OSTEOSARCOMA; PUBLICATION BIAS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84904725118     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1717-3     Document Type: Article

References (29)

1. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol H O. 2010;8(10):705-18.
2. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma. 2012;2012:359739.
3. Hameed M, Dorfman H. Primary malignant bone tumors - recent developments. Semin Diagn Pathol. 2011;28(1):86-101.
4. Weeden S, Grimer RJ, Cannon SR, Taminiau AH, Uscinska BM. The effect of local recurrence on survival in resected osteosarcoma. Eur J Cancer (Oxford, England: 1990). 2001;37(1):39-46.
5. Harting MT, Blakely ML, Jaffe N, Cox Jr CS, Hayes-Jordan A, Benjamin RS, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41(1):194-9. (Pubitemid 43067516)
6. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-73. (Pubitemid 43139720)
7. Egeblad M, Werb Z. New functions for thematrixmetalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-74. (Pubitemid 37328786)
8. Viros D, Camacho M, Zarraonandia I, Garcia J, Quer M, Vila L, et al. Prognostic role of MMP-9 expression in head and neck carcinoma patients treated with radiotherapy or chemoradiotherapy. Oral Oncol. 2013;49(4):322-5.
9. Vilen ST, Salo T, Sorsa T, Nyberg P. Fluctuating roles of matrix metalloproteinase-9 in oral squamous cell carcinoma. Sci World J. 2013;2013:920595.
10. Gao XH, Yang XQ, Wang BC, Liu SP, Wang FB. Overexpression of twist and matrix metalloproteinase-9withmetastasis and prognosis in gastric cancer. APJCP. 2013;14(9):5055-60.
11. Huang Y, Wang JP. Expressions of MDM2 and MMP-9 in osteosarcoma tissue and clinical significances [article in Chinese]. J Pract Oncol. 2009;23(1):35-7.
12. Chen L, Lin JH, Zhang S. Expression of MMP-9 and TIMP-1 and their clinical significance in osteosarcoma [article in Chinese]. Chin J Exp Surg. 2004;21(12):1522-3.
13. Luo XZ, Ni JD. Expression and clinical significance of MMP-9 and PCNA in osteosarcoma [article in Chinese]. J Clin Res. 2006;23(5):682-4.
14. Li WX, Ye ZM, Yang DS, Tao HM. The expression of vascular endothelial growth factor, matrix metalloproteinases 2, 9 in osteosarcoma [article in Chinese]. Zhejiang Med J. 2006;28(9):691-4.
15. Foukas AF, Deshmukh NS, Grimer RJ, Mangham DC, Mangos EG, Taylor S. Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells. J Bone Joint Surg Br Vol. 2002;84(5):706-11.
16. Kushlinsky NE, Solovyov YN, Babkina IV, Gershtein ES, Bulicheva IV. Matrix metalloproteinases 2, 7, 9 and tissue inhibitor of matrix metalloproteinase-1 in the sera of patients with bone tumors. Bull Exp Biol Med. 2010;149(2):233-5.
17. Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28(1):33-42.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clin Res ed). 2003;327(7414):557-60. (Pubitemid 37088507)
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-48.
20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88. (Pubitemid 17189972)
21. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clin Res ed). 1997;315(7109):629-34. (Pubitemid 27387172)
22. Jaffe N. Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res. 2009;152:239-62.
23. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284(5751):67-8. (Pubitemid 10098769)
24. Stetler-Stevenson WG. Type IV, collagenases in tumor invasion and metastasis. Cancer Metastasis Rev. 1990;9(4):289-303.
25. Zhang Q-W, Liu L, Chen R, Wei Y-Q, Li P, Shi H-S, et al. Matrix metalloproteinase-9 as a prognostic factor in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(6):2903-8.
26. Song J, Su H, Zhou Y-Y, Guo L-L. Prognostic value of matrix metalloproteinase 9 expression in breast cancer patients: a meta-analysis. Asian Pac J Cancer Prev. 2013;14(3):1615-21.
27. Peng WJ, Zhang JQ, Wang BX, Pan HF, Lu MM, Wang J. Prognostic value of matrix metalloproteinase 9 expression in patients with non-small cell lung cancer. Clinica Chim Acta Int J Clin Chem. 2012;413(13-14):1121-6.
28. Li CY, Yuan P, Lin SS, Song CF, Guan WY, Yuan L, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(2):735-41.
29. Fu HL, Shao L, Wang Q, Jia T, Li M, Yang DP. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2013;34(6):3817-21.